| Followers | 34 |
| Posts | 2049 |
| Boards Moderated | 0 |
| Alias Born | 12/03/2013 |
Monday, June 08, 2015 3:14:07 PM
Sal they are releasing "full data" on BESTFIT. So while not new, they will be expanding their analysis a bit and the CEO made a comment at Jeffries that shareholders will be very interested in seeing the data. It's not new data that will drive this price right now, it's the fact that the market is finally noticing how undervalued this stock is. Before jbem shed light on it, daily volume was embarrassing. Now people know that there is a low float stock with 3 late stage programs including a Phase 3 for multi billion indications that has a market cap of a miniscule $130M. As word spreads this will correct and quickly, as it's started doing over the last two weeks.
It sounds like you may either have sold too soon or are looking to add. Trust me friend, the time is now. This will be in the teens very soon.
It sounds like you may either have sold too soon or are looking to add. Trust me friend, the time is now. This will be in the teens very soon.
Recent TNXP News
- Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development • GlobeNewswire Inc. • 04/15/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 11:05:34 AM
- Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026 • GlobeNewswire Inc. • 03/31/2026 11:00:00 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/30/2026 12:00:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 11:00:28 AM
- Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain • GlobeNewswire Inc. • 03/26/2026 11:00:00 AM
- Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026 • GlobeNewswire Inc. • 03/23/2026 08:32:42 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/20/2026 09:12:47 PM
- Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026 • GlobeNewswire Inc. • 03/18/2026 08:58:49 PM
- Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026 • GlobeNewswire Inc. • 03/17/2026 08:35:00 PM
- Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing • GlobeNewswire Inc. • 03/13/2026 12:35:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2026 10:01:04 AM
- Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights • GlobeNewswire Inc. • 03/12/2026 09:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/12/2026 09:29:52 PM
- Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th • GlobeNewswire Inc. • 03/10/2026 02:21:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/10/2026 12:05:34 PM
- Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia • GlobeNewswire Inc. • 03/10/2026 12:00:00 PM
- Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting • GlobeNewswire Inc. • 03/09/2026 08:30:00 PM
- Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development • GlobeNewswire Inc. • 03/05/2026 09:15:00 PM
- Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting • GlobeNewswire Inc. • 03/03/2026 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 11:05:34 AM
- Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market • GlobeNewswire Inc. • 03/03/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2026 12:03:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2026 12:03:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2026 12:02:06 PM
